BCG020
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors
(AACR 2024)
- "We observed that BCG020 treatment (10 mg/kg) potently inhibited growth of EGFR+CD70+ tumors. Taken together, these data indicate that BCG020 is a first-in-class bispecific antibody with potential to treat solid tumors with high expression of EGFR and CD70."
IO biomarker • Oncology • Solid Tumor • CD27 • CD70 • EGFR
1 to 1
Of
1
Go to page
1